Neurocritical Care News

The FDA in August issued a final rule to establish a new category of over-the-counter hearing aids, which will enable consumers with perceived mild to moderate hearing impairment to purchase hearing aids directly from stores or online retailers.

LAS VEGAS — Lesser-known cannabinoids are showing potential for treating neurological disease, inflammation, pain, cancer and infection, according to dermatologist Jeanette Jacknin, MD.

Cerveau Technologies Inc. announced a partnership with Alnylam Pharmaceuticals, which will use Cerveau’s investigational imaging agent in positron emission tomography scans to evaluate neurofibrillary tangles in the brain.

Canadian-based Neurolytixs Inc. announced it has secured a United States patent for technology that can identify mild traumatic brain injuries more accurately and rapidly, particularly in young athletes with concussions.

Aptinyx Inc. announced it has completed enrollment in the company’s ongoing phase 2 study of NYX-458, an oral treatment for cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.

An at-home, artificial intelligence-based system identified individuals with Parkinson’s disease and predicted disease severity and progression using nocturnal breathing signals, according to a study in Nature Medicine.

Gate Neurosciences is developing a new portfolio of next-generation therapeutics to treat synaptic dysfunction in patients with central nervous system disorders, the company announced in a press release.

Researchers at Aston University in England have received funding to explore new methods of recording electrical signals emitted from brain cells, which could lead to potential treatment for conditions like epilepsy and schizophrenia.

The FDA has granted premarket approval for Abbott’s Proclaim Plus spinal cord stimulation system, which can treat chronic pain across up to six areas of the body and is programmable to adjust to a person’s needs, the company announced in a release.

Biomarkers collected on the day of traumatic brain injury had significant prognostic value for death and unfavorable outcome but not for incomplete recovery at 6 months, according to a study published in The Lancet Neurology.